Logotype for IDEAYA Biosciences Inc

IDEAYA Biosciences (IDYA) R&D Day 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for IDEAYA Biosciences Inc

R&D Day 2026 summary

17 Nov, 2026

Pipeline overview and program updates

  • 2026 pipeline includes darovasertib, DLL3 ADC, PRMT5 inhibitor IDE892, MAT2A inhibitor IDE397, dual KAT6/7 inhibitor IDE574, CDKN2A-directed dual-CDK candidate IDE101 and a preclinical next-generation RAS program.

  • IDE892 is in Phase 1/2 and IDE397 in Phase 2; IDE574 is in Phase 1/2 monotherapy evaluation, including breast cancer, and is being studied with fulvestrant/SERD and RAS inhibitors.

  • IDE101 is designed for CDKN2A-deficient cancers; its IND is targeted for H1 2027, with combinations planned with IDE892 and RAS inhibitors. CDKN2A loss is estimated in ~70% of pancreatic cancer.

  • IDE892 combinations under evaluation include IDE397, pan-RAS, KRAS G12D and IDE101; IDE574 is also being studied in monotherapy and combination settings.

Clinical trial data and development milestones

  • IDE892 monotherapy: 31 patients, 18 treatment-related adverse events and 2 Grade 3 events; no Grade 4/5 events, DLTs or MTD reached. Dose-dependent exposure supported QD dosing, with target EC90 coverage at DL3 or higher; expansion began at DL3.

  • A heavily pretreated, MTAP-positive cholangiocarcinoma patient had a confirmed IDE892 partial response, deepening from -31% at Week 6 to -60% at Week 12; a separate patient had a confirmed response on IDE892/IDE397.

  • IDE574 monotherapy: 32 patients, 18 treatment-related adverse events and 3 Grade 3 events; one DLT and no Grade 4/5 events or MTD reached. A 5L ER-positive breast cancer patient had a -40% partial response, with KAT6/7 target engagement.

  • IDE892 showed no drug-drug interaction with IDE397 at the first combination dose; exposure-linked SDMA suppression was observed.

  • IDE892/IDE397 MTAP-deleted NSCLC expansion is targeted for H1 2027; IDE892/pan-RAS first-patient dosing for Q4 2026 and IDE892/KRAS G12D for Q1 2027.

R&D strategy and innovation priorities

  • Combination strategy pairs tumor-suppressor-loss targets with oncogene inhibition to address heterogeneity and adaptive resistance across PDAC, NSCLC and CRC; RAS plus PRMT5 clinical proof of concept was cited in MTAP/KRAS pancreatic cancer.

  • IDE892 was designed for MTA-supercooperative and SAM-anticooperative binding; MTA increased PRMT5 affinity 1,400-fold. Preclinical studies showed MTAP-null selectivity and combination regressions across KRAS models.

  • IDE574 dual KAT6/7 inhibition targets lineage plasticity and adaptive resistance; preclinical RAS combinations showed durable activity in CRC and KRAS NSCLC models. ~50% of acquired pan-RAS inhibitor resistance events were attributed to adaptive plasticity in preclinical evaluation.

  • IDE101’s dual-CDK profile suppressed E2F and S-phase activity while avoiding CDK6-linked myelosuppression in preclinical assays; RAS inhibitor combinations showed durable preclinical control.

  • AI/ML integrates physics-based free-energy perturbation, active learning, generative design and HARMONY drug-property prediction; it accelerated IDE574 discovery by eight months and increased KAT6/7 FEP calculations by >100-fold.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from IDEAYA Biosciences